Invited commentary  by Lindblad, Bengt
JOURNAL OF VASCULAR SURGERY
1298 Lindblad May 2013INVITED COMMENTARYBengt Lindblad, MD, PhD, Malmö, SwedenIn this issue of the Journal of Vascular Surgery, El Batti and
coworkers report on the not-always-benign outcome of type II
endoleak after endovascular aneurysm repair (EVAR) in 700
patients, of whom 201 patients had type II endoleaks. This is an
important problem. Today, there is no consensus on the handling
of type II endoleaks, and recent reviews agree at least on one
issue—the lack of hard facts on how to handle type II endoleaks.1,2
Worldwide, at this time, about 330,000 patients with abdom-
inal aortic aneurysms (AAAs), mainly Caucasians, are repaired
annually, among whom about 150,000 patients are repaired with
EVAR. The frequency of use of EVAR is increasing but varies
widely among countries, ranging from 20% in Finland up to 60%
in the United States, France, and Australia. The frequency also
varies greatly among hospitals. At the Skåne University Hospital,
Malmö, Sweden, currently 94% of all AAA patients are treated
with EVAR. Of the approximately 150,000 EVARs performed
annually, 10% to 25% are detected with a type II endoleak accord-
ing to different reports. In the report by El Batti et al, patients with
type II endoleaks were older, more often female, had larger aneu-
rysms, and had more patent lumbar arteries than those without
endoleak. One problem is that 182 patients with type I and III
endoleaks are included (about 25% of patients in the groups with
and without type II endoleak). This clouds the results, and sepa-
rate analyses without including type I or III endoleak patients
would have removed some of the uncertainty.
It is intriguing that normally during open aneurysm repair,
suture-ligate back-bleeding lumbar and inferior mesenteric arteries
are needed, but after EVAR, “only 10% to 25%” are found to have
type II endoleak. Is our surveillance imaging too poor? May
contrast-enhanced ultrasonography add information? Are we cate-
gorizing endoleaks correctly?
Should transient, persistent, or recurrent type II endoleaks be
handled differently? When should treatment of type II endoleak
be recommended? Is treatment only required of those patients
having both endoleak and aneurysmal sac enlargement? In the anal-
ysis by El Batti and coworkers, the effectiveness of endovascular
treatment was surprisingly low, and in only 22% stopped further
aneurysmal sac enlargement, a ﬁnding in agreement with Aziz
et al3 but a little less effective than in the report by Sarac et al.4 Treat-
ment of a type II endoleak with laparoscopic technique, emboliza-
tion or glue, and endovascular or open conversion carries
a substantial morbidity and mortality.1-6
Nevertheless, an aneurysm rupture is what we really aim to
prevent. In the present series by El Batti et al, four ruptures
compared with ﬁve were seen in the type II endoleak group vs
the group without type II endoleak. It is presented in a summary
of other reports (Table VII) on 8 ruptures out of 7500 EVAR-treated patients. In recent publications, no ruptures from type II
endoleak have been reported.3,4 Chaar et al analyzed 12 ruptures
of which only two were due to type II endoleak.5 A decade ago,
stent migration was considered a more important factor for rupture
than endoleaks. In an analysis of a registry of over 10,000 EVAR
patients, 32% had any type of endoleak. However, only 20% of
these showed aneurysm sac enlargement6 compared with 40% re-
ported by El Batti et al. Importantly, in this registry,6 aneurysm
sac enlargement was seen in over 40% of patients 5 years after
EVAR; thus, many without any endoleak detected showed sac
growth!6 Data regarding rupture and mortality were not possible
to analyze in this registry.
Prospective studies of different planned treatment strategies of
different subgroups of patients with type II endoleak are needed.
What outcome measures should be the aim? Sac enlargement is
an uncertain outcome measure. Rupture has such a low frequency
that it cannot be used as an outcome measure; the size of such
a study would be enormous. Maybe the only way to further answer
these important questions is performing large studies as presented
by El Batti and coworkers. Unfortunately, their study still leaves us
confused, but on a higher level of knowledge. Further studies and/
or registries using planned treatment strategies are required, to
learn the value of and the risk from either being more conservative
or more aggressive in the treatment of type II endoleaks after
EVAR.REFERENCES
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